Effects of dopamine receptor agonists and antagonists at peripheral neuronal and vascular dopamine receptors in the anaesthetised dog.
The interactions between several putative dopamine receptor agonists and antagonists have been examined at neuronal and vascular dopamine receptors in the femoral and mesenteric vascular beds, respectively, of anaesthetised dogs. N,N-di-n- propyldopamine (DPDA) and apomorphine caused vasodilatation in both vascular beds. Cis alpha-flupenthixol, fluphenazine, and sulpiride were much more potent at antagonising DPDA at neuronal than at vascular dopamine receptors. Fluphenazine and sulpiride were as potent against apomorphine as against DPDA at neuronal receptors, but cis alpha-flupenthixol was much less effective. Fluphenazine antagonised the vasodilator effect of apomorphine in the mesenteric vascular bed, but cis alpha-flupenthixol and sulpiride did not, even when used in doses much larger than were effective against DPDA. Further experiments, in dogs pretreated with phenoxybenzamine and propranolol, revealed that cis alpha-flupenthixol, fluphenazine, and sulpiride also antagonised the mesenteric vasodilator effects of dopamine, 2-amino-5,6-dihydroxy-1,2,3,4-tetrahydronaphthalene, 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene, and 2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine, suggesting a common site of action of these drugs and DPDA. Only fluphenazine antagonised responses to apomorphine. The results support the view that neuronal and vascular dopamine receptors in the dog are different. They also show that apomorphine stimulates different receptors from DPDA in the mesenteric vascular bed and, perhaps, in the femoral vascular bed as well.
D000758:Anesthesia; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology; D001058:Apomorphine / Q000494:pharmacology; D004285:Dogs; D004298:Dopamine / Q000031:analogs & derivatives / Q000494:pharmacology; D004347:Drug Interactions; D005260:Female; D005263:Femoral Artery / Q000294:innervation / Q000502:physiology*; D005475:Flupenthixol / Q000494:pharmacology; D005476:Fluphenazine / Q000494:pharmacology; D008297:Male; D008638:Mesenteric Arteries / Q000294:innervation / Q000502:physiology*; D009474:Neurons / Q000502:physiology*; D010525:Peripheral Nerves / Q000502:physiology*; D011954:Receptors, Dopamine / Q000187:drug effects / Q000502:physiology*; D012039:Regional Blood Flow / Q000187:drug effects; D013469:Sulpiride / Q000494:pharmacology
D000959:Antihypertensive Agents; D011954:Receptors, Dopamine; C020895:N,N-di-n-propyldopamine; D013469:Sulpiride; D005475:Flupenthixol; D001058:Apomorphine; D005476:Fluphenazine; D004298:Dopamine